IL2 and colorectal cancer: For example, using the syngeneic CT-26 colorectal cancer model, the next generation not-alpha IL2 agent THOR-707/SAR’245 resulted in a significant increase in PD-L1 and CTLA4 receptor gene expression when combined with anti-PD-1 therapy, with the latter also increased with single-agent THOR-707/SAR’245 treatment (13).